Corcept Q3 EPS Surges Past Estimates; Scrutiny of Drivers Needed

What happened

Corcept Therapeutics reported Q3 2026 earnings per share of $1.01, significantly beating the Zacks consensus estimate of $0.68 and up from $0.16 a year ago. This dramatic improvement comes after a period of transformation, including the submission of an NDA for relacorilant in Cushing's with an FDA decision expected by end-2025 and a planned ovarian cancer filing. The prior DeepValue report had rated the stock HOLD/NEUTRAL, citing risks of generic pressure on Korlym and reimbursement headwinds while acknowledging the pipeline catalyst. The Q3 beat suggests either robust performance in the base business or a positive pipeline development driving earnings, but the news release lacks detail on revenue composition and whether the beat stems from core operations or one-time items. Investors should seek clarity on relacorilant's approval status and Korlym's resilience before revising the thesis.

Implication

Investors should view this quarter's outperformance as a positive signal but tempered by the need for granularity on drivers. If the earnings surge is driven by relacorilant approval and successful launch, the thesis shifts towards BUY, as diversification reduces single-asset risk. Conversely, if the beat is due to one-time items or atypical Korlym dynamics, the previous HOLD/NEUTRAL stance may remain appropriate. Monitoring continued revenue growth and margin expansion in subsequent quarters will be critical. Additionally, confirmation of relacorilant's FDA outcome and its commercial trajectory will be key catalysts.

Thesis delta

The previous HOLD stance was contingent on binary regulatory risk and generic erosion. The Q3 EPS of $1.01, versus $0.68 expected and $0.16 prior year, indicates a material improvement that, if sustained, could support a BUY rating. However, without clarity on revenue drivers and relacorilant status, we maintain a cautious view, awaiting confirmation of operational strength.